CN112759663B - Liuan Guapian polysaccharide with immunoregulatory activity and preparation method and application thereof - Google Patents
Liuan Guapian polysaccharide with immunoregulatory activity and preparation method and application thereof Download PDFInfo
- Publication number
- CN112759663B CN112759663B CN202110081907.5A CN202110081907A CN112759663B CN 112759663 B CN112759663 B CN 112759663B CN 202110081907 A CN202110081907 A CN 202110081907A CN 112759663 B CN112759663 B CN 112759663B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- liuan guapian
- guapian
- liuan
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 87
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 85
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000004957 immunoregulator effect Effects 0.000 title description 5
- 230000000694 effects Effects 0.000 claims abstract description 19
- 230000007365 immunoregulation Effects 0.000 claims abstract description 11
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 3
- 230000002584 immunomodulator Effects 0.000 claims abstract description 3
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 4
- 241001122767 Theaceae Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 230000005965 immune activity Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000002865 immune cell Anatomy 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- 244000269722 Thea sinensis Species 0.000 description 18
- 210000002540 macrophage Anatomy 0.000 description 16
- 235000013616 tea Nutrition 0.000 description 14
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 230000008782 phagocytosis Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- 235000009569 green tea Nutrition 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- -1 and in recent years Chemical class 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The invention discloses Liuan Guapian polysaccharide with immunoregulation activity, and a preparation method and application thereof, wherein the molecular weight of the polysaccharide is 2.35 multiplied by 105Da. The Liuan Guapian polysaccharide can regulate the cellular immune activity, and the characteristic of the Liuan Guapian polysaccharide for enhancing immune cells in vitro enables the Liuan Guapian polysaccharide to be used as an immunomodulator, can be widely applied to the fields of health-care foods and medicines, and has important research, development and utilization prospects.
Description
Technical Field
The invention relates to Liuan Guapian polysaccharide with immunoregulation activity and a preparation method and application thereof, belonging to the technical field of food and medicine.
Background
The immunity is an important physiological function of human body, and the organism can recognize self and non-self components by means of the function, thereby destroying and rejecting heterogeneous substances entering the organism or damaged and variant cells generated by the organism to maintain the health of the human body. Walford proposed the theory of immunosenescence in 1962, and thought that the decline of immune function is an important factor causing body senescence, with the increase of age, the immune organs age, the number of immune cells is reduced, the immune function of the body is gradually weakened, and the incidence of infectious diseases and tumors is gradually increased. The decline of the immune function can further accelerate the aging of the body.
The medicine for improving the human body immune function can bring a plurality of side effects such as drug resistance, drug dependence, teratogenicity and carcinogenicity while regulating the immune activity. Therefore, the search for a natural, highly effective, non-toxic immune modulator is the focus of research by researchers. With the intensive research on natural active substances, more and more researchers pay attention to polysaccharides, and in recent years, polysaccharides of green tea, black tea and the like have been proved to have good immunoregulatory efficacy.
Liuan Guapian, abbreviated as Guapian and piece tea, is a traditional historical famous tea in China, also one of ten famous teas in China, is produced from Dabie mountain area in Liuan City, Anhui province, and is a special tea type of green tea. In all tea leaves in the world, Liuan Guapian is the only tea without buds and stalks and is prepared from single raw leaves. The bud removal not only keeps a single-piece body, but also has no green grass flavor; the stems are lignified in the making process, and after the stems are removed, the tea can be ensured to have thick but not bitter taste and fragrant but not astringent taste. As a local characteristic biomass resource, the immunocompetence of the green tea polysaccharide is not reported at present, so that the green tea polysaccharide has potential research and development values.
Disclosure of Invention
The invention aims to provide Liuan Guapian polysaccharide with immunoregulation activity and a preparation method and application thereof. The Liuan Guapian polysaccharide found by the invention has good immunoregulation activity, has NO obvious cytotoxicity to RAW264.7 macrophages when the Liuan Guapian polysaccharide is 25-400 mu g/mL in vitro immunocompetence detection, can greatly increase NO release amount of RAW264.7 macrophages, activates immunocyte activity, and has important research, development and utilization prospects.
In order to realize the purpose of the invention, the following technical scheme is adopted:
a Liuan Guapian polysaccharide with immunoregulatory activity and molecular weight of 2.35 × 105Da, an infrared spectrum shows that the polysaccharide has a remarkable infrared characteristic absorption peak.
The preparation method of Liuan Guapian polysaccharide with immunoregulation activity, provided by the invention, comprises the following steps:
(1) crushing Liuan Guapian tea leaves by a crusher, and sieving by a 80-mesh sieve to obtain powder;
(2) soaking the obtained powder in 50-80 deg.C anhydrous ethanol for 2-4h, filtering with gauze, and vacuum drying to obtain filter residue;
(3) leaching the obtained filter residue in hot water at 50-100 deg.C for 1-5 hr according to a material-liquid ratio of 1g:10-40mL, repeating for 2-3 times, and mixing extractive solutions;
(4) concentrating the extracting solution obtained in the step (3) to 1/3-1/10, adding ethanol into the obtained concentrated solution until the final volume concentration of the ethanol is 75-90%, standing for 8-12h at 4 ℃, centrifuging for 10-30min at 8000rpm of 5000-;
(5) dissolving the precipitate obtained in the step (4) with water, centrifuging to remove insoluble substances, and freeze-drying to obtain crude Liuan Guapian polysaccharide;
(6) preparing the crude polysaccharide of the Liuan Guapian tablet obtained in the step (5) into a crude polysaccharide solution with the concentration of 20-40mg/mL by using deionized water, centrifuging and filtering by using a 0.22 mu m filter membrane, putting the obtained trapped solution into a DEAE-cellulose 52 ion exchange column for purification, wherein the mobile phase is a 0.3mol/L sodium chloride solution, and the flow rate is 0.5-1.0 mL/min; collecting the product, purifying by using a dialysis bag with the molecular weight cutoff of 3.5-5.5 kDa, and freeze-drying to obtain the Liuan Guapian polysaccharide.
Preferably, in the step (2), the temperature of the vacuum drying is 60-70 ℃ and the time is 2-4 h.
Preferably, in the steps (5) and (6), the rotation speed of the centrifugation is 7000-10000 rpm.
The Liuan Guapian polysaccharide found by the invention has good immunoregulation activity and can be used for preparing an immunomodulator.
The invention has the beneficial effects that:
1. the invention discovers that the Liuan Guapian polysaccharide has obvious immunoregulation effect on macrophage RAW264.7, has no toxicity on normal cells, and has higher survival rate of the macrophage even under the condition of high concentration (400 mu g/mL); the immune activity test shows that the Liuan Guapian polysaccharide also shows obvious stimulation effect at low concentration (25 mu g/mL), which indicates that the Liuan Guapian polysaccharide can regulate the cellular immune activity. At present, no immunoreaction report of the Liuan Guapian polysaccharide is found.
2. The Liuan Guapian polysaccharide prepared by the method has only one absorption peak and the molecular weight is 2.35 multiplied by 10 through High Performance Liquid Chromatography (HPLC) detection5Da, has strong immunoregulation activity, and can be used as a novel immunoregulator to be applied to health-care foods and medicines.
3. The method for preparing the active polysaccharide has high efficiency and stable activity.
Drawings
FIG. 1 is a high performance liquid chromatogram of Liuan Guapian polysaccharide obtained in example 1.
FIG. 2 is a graph showing the toxicity test of Liuan Guapian polysaccharide obtained in example 1 on macrophages. As can be seen from FIG. 2, Liu' an Guapian polysaccharide has no toxic effect on the macrophage RAW264.7, and can promote the growth of RAW264.7 macrophages within a certain concentration range.
FIG. 3 is a graph showing the measurement of the NO release amount of macrophages by the Liuan Guapian polysaccharide obtained in example 1. As can be seen from FIG. 3, compared with the blank group, Liuan Guapian polysaccharide has an obvious promotion effect on NO secretion of macrophages, which indicates that Liuan Guapian polysaccharide has stronger immunoregulatory activity.
FIG. 4 shows the phagocytosis of macrophages by Liuan Guapian obtained in example 1. As can be seen from FIG. 4, phagocytosis of macrophages after 24h of Liuan Guapian polysaccharide action is obviously increased and is concentration-dependent, and compared with the control group, the phagocytosis activity of Liuan Guapian polysaccharide is obviously increased and is dose-dependent when the concentration of Liuan Guapian polysaccharide is 400 mug/mL.
FIG. 5 is the morphological observation of macrophages after phagocytosis in example 1, wherein FIG. 5a corresponds to the blank control group, FIG. 5b corresponds to the 1 μ g/mLLPS group, FIG. 5c corresponds to the 100 μ g/mL Liuan Guapian polysaccharide group, and FIG. 5d corresponds to the 400 μ g/mL Liuan Guapian polysaccharide group. As can be seen from fig. 5, the cells of the blank control group were round and had a normal morphology, whereas the morphology of the cells was significantly changed after the treatment with the polysaccharide of liuan guapian, and it can be clearly seen that many spikes were generated around the cells and had a concentration dependence.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with figures are described in detail below. The following disclosure is merely exemplary and illustrative of the inventive concept, and those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
Example 1
In the embodiment, Liuan Guapian tea is taken as a raw material, and Liuan Guapian polysaccharide is extracted, separated and purified according to the following steps:
(1) 100g of Liuan Guapian tea leaves are ground by a grinder and then sieved by a 80-mesh sieve to obtain powder.
(2) Soaking the obtained powder in 1L of 70 deg.C anhydrous ethanol for 2 hr, filtering with gauze, and vacuum drying at 70 deg.C for 3 hr to obtain filter residue.
(3) Leaching the obtained filter residue in hot water at 90 deg.C for 2h according to a material-liquid ratio of 1g:20mL, repeating for 2 times, and mixing extractive solutions.
(4) Concentrating the extracting solution obtained in the step (3) to 1/10 volume, adding ethanol into the obtained concentrated solution until the final volume concentration of the ethanol is 75 volume%, standing at 4 ℃ for 10h, centrifuging at 10000rpm for 10min, and collecting precipitate.
(5) And (4) dissolving the precipitate obtained in the step (4) with water, centrifuging at 10000rpm for 10min to remove insoluble substances, and freeze-drying to obtain the crude Liuan Guapian polysaccharide.
(6) Preparing the crude polysaccharide of the Liuan Guapian slices obtained in the step (5) into a crude polysaccharide solution with the concentration of 40mg/mL by using deionized water, centrifuging for 1min at 10000rpm, filtering by using a 0.22 mu m filter membrane, and purifying the obtained trapped solution in a DEAE-cellulose 52 ion exchange column at the flow rate of 0.75mL/min and with the mobile phase of 0.3mol/L sodium chloride solution; collecting the product, purifying by using a dialysis bag with the molecular weight cutoff of 3.5kDa, and freeze-drying to obtain the Liuan Guapian polysaccharide.
Fig. 1 is a high performance liquid chromatogram of liuan guapian polysaccharide obtained in this example, and it can be seen from the figure that: the polysaccharide sample has a single absorption peak with retention time of 5.45min, and its molecular weight is 2.35 × 105Da。
1. Cytotoxicity assays
The Liuan Guapian polysaccharide was diluted to different concentrations with growth medium. RAW264.7 cells were cultured in growth medium at 37 ℃ and then seeded into 96-well plates (1X 10)4Cells/well) and in 96-well plates, respectivelyIncreasing concentrations of 100. mu.L Liuan Guapian polysaccharide (25-400. mu.g/mL) were added for treatment. Meanwhile, 1. mu.g/mL of LPS was used as a positive control group.
After 24h incubation, cell viability was determined using the MTT method: the cell supernatant was first removed and 100mL of MTT solution (0.5mg/mL) was added to each well and incubated for an additional 4 h. Next, the supernatant was discarded and 100 μ L DMSO was added to the cell culture, followed by shaking for 10min away from light until no visible particulate matter was detected. The absorbance at 570nm was measured using a microplate reader. The toxic effect result of Liuan Guapian polysaccharide on macrophages is shown in figure 2, and within the concentration range of 25 mug/mL-400 mug/mL, Liuan Guapian polysaccharide has no toxic effect on macrophages and has promotion effect.
2. NO production amount measurement (Griess method)
The Liuan Guapian polysaccharide was diluted to different concentrations with growth medium. RAW264.7 cells were plated in 48-well plates (1X 10)5Individual cells/well) were preincubated at 37 ℃ for 24 h. Then 200. mu.L of Liuan Guapian polysaccharide (25-400. mu.g/ml) with increasing concentration is added into the well plate for 24 h. Meanwhile, cells were treated with LPS (1. mu.g/mL) for 24h under the same conditions as a positive control group. The cell culture supernatant was then collected and mixed with an equal volume of Griess reagent, incubated at room temperature for 30min, and measured with a microplate reader at 540 nm. The results are shown in FIG. 3.
As can be seen from fig. 3, the production of NO in the blank control was much lower than the positive control of LPS and hexaampere papyrhyacinthine polysaccharide treated groups, with significant differences. Meanwhile, after the Liuan Guapian polysaccharide with different concentrations is treated for 24 hours, the generation of NO is concentration-dependent, and the NO release amount of macrophages is gradually increased. The experimental result shows that the Liuan Guapian polysaccharide has a remarkable stimulation effect on RAW264.7 cells, and particularly has a promoting effect on the generation of NO.
3. Phagocytic Activity assay and morphological Observation
Phagocytic capacity of macrophages was measured by a neutral red uptake assay. Mixing cells (1X 10) with Liuan Guapian polysaccharide (25-400 μ g/mL) or LPS (1 μ g/mL)5Individual cells/well) were placed in 48-well plates in an incubator (5% CO) at 37 ℃2) And (4) performing medium incubation for 24 h. Removing the supernatantSolution, and neutral red solution (v/v, 0.05%) was added to the wells and incubation continued for 20 min. Then, the supernatant was discarded and the cells were washed three times with PBS to remove excess neutral red not phagocytosed by RAW264.7 cells, added to the lysate, and lysed at 4 ℃ for 2 h. Cells were incubated overnight at room temperature and assayed at 540 nm. The morphology of RAW264.7 cells phagocytosing neutral red was observed by an inverted fluorescence microscope.
As can be seen from fig. 4, the phagocytosis index of the polysaccharide-treated Liuan Guapian group was significantly higher than the blank after 24h and showed good concentration dependence. Meanwhile, the maximum concentration of polysaccharide in Liuan Guapian (400 mu g/mL) is significantly higher than that in the LPS positive control group. The Liuan Guapian polysaccharide can remarkably promote the phagocytic capacity of RAW264.7 cells.
To further observe the morphological changes of the cells during phagocytosis, the morphology of RAW264.7 cells was examined. As can be seen in fig. 5, the blank control cells were round with normal morphology (fig. 5 a). However, the cell morphology after treatment with LPS (FIG. 5b, LPS concentration 1. mu.g/mL) and Liuan Guapian polysaccharide (FIGS. 5c-d, Liuan Guapian polysaccharide concentrations 100, 400. mu.g/mL, respectively) changed significantly. It is clearly seen that a number of spikes are produced around the cell, and this structure is advantageous in increasing the contact area of the cell with the external environment, contributing to phagocytosis. When the concentration of Liuan Guapian polysaccharide reached 400. mu.g/mL, the spikes were significantly increased (FIG. 5d), exhibiting good concentration dependence.
Example 2
In the embodiment, Liuan Guapian tea is taken as a raw material, and Liuan Guapian polysaccharide is extracted, separated and purified according to the following steps:
(1) 100g of Liuan Guapian tea leaves are ground by a grinder and then sieved by a 80-mesh sieve to obtain powder.
(2) Soaking the obtained powder in 1L of 70 deg.C anhydrous ethanol for 2 hr, filtering with gauze, and vacuum drying at 70 deg.C for 3 hr to obtain filter residue.
(3) Leaching the obtained filter residue in hot water at 80 deg.C for 3h according to a material-liquid ratio of 1g:20mL, repeating for 3 times, and mixing extractive solutions.
(4) Concentrating the extracting solution obtained in the step (3) to 1/10 volume, adding ethanol into the obtained concentrated solution until the final volume concentration of the ethanol is 75 volume%, standing at 4 ℃ for 12h, centrifuging at 8000rpm for 10min, and collecting precipitate.
(5) And (4) dissolving the precipitate obtained in the step (4) with water, centrifuging at 10000rpm for 10min to remove insoluble substances, and freeze-drying to obtain the crude Liuan Guapian polysaccharide.
(6) Preparing the crude polysaccharide of the Liuan Guapian slices obtained in the step (5) into a crude polysaccharide solution with the concentration of 40mg/mL by using deionized water, centrifuging for 1min at 10000rpm, filtering by using a 0.22 mu m filter membrane, and purifying the obtained trapped solution in a DEAE-cellulose 52 ion exchange column at the flow rate of 0.5mL/min and with the mobile phase of 0.3mol/L sodium chloride solution; collecting the product, purifying by using a dialysis bag with the molecular weight cutoff of 3.5kDa, and freeze-drying to obtain the Liuan Guapian polysaccharide.
The molecular weight of the Liuan Guapian polysaccharide obtained in the example is tested to be 2.35 multiplied by 105Da and has good immunoregulation activity.
Example 3
In the embodiment, Liuan Guapian tea is taken as a raw material, and Liuan Guapian polysaccharide is extracted, separated and purified according to the following steps:
(1) 100g of Liuan Guapian tea leaves are ground by a grinder and then sieved by a 80-mesh sieve to obtain powder.
(2) Soaking the obtained powder in 2L of 80 deg.C anhydrous ethanol for 3 hr, filtering with gauze, and vacuum drying at 70 deg.C for 3 hr to obtain filter residue.
(3) Leaching the obtained filter residue in hot water at 80 deg.C for 2h according to a material-liquid ratio of 1g:30mL, repeating for 3 times, and mixing extractive solutions.
(4) Concentrating the extracting solution obtained in the step (3) to 1/10 volume, adding ethanol into the obtained concentrated solution until the final volume concentration of the ethanol is 80%, standing at 4 ℃ for 8h, centrifuging at 8000rpm for 20min, and collecting precipitate.
(5) And (4) dissolving the precipitate obtained in the step (4) with water, centrifuging at 10000rpm for 10min to remove insoluble substances, and freeze-drying to obtain the crude Liuan Guapian polysaccharide.
(6) Preparing the crude polysaccharide of the Liuan Guapian slices obtained in the step (5) into a crude polysaccharide solution with the concentration of 50mg/mL by using deionized water, centrifuging for 1min at 10000rpm, filtering by using a 0.22 mu m filter membrane, and purifying the obtained trapped solution in a DEAE-cellulose 52 ion exchange column at the flow rate of 1mL/min, wherein the mobile phase is a 0.3mol/L sodium chloride solution; collecting the product, purifying by using a dialysis bag with the molecular weight cutoff of 3.5kDa, and freeze-drying to obtain the Liuan Guapian polysaccharide.
The molecular weight of the Liuan Guapian polysaccharide obtained in the example is tested to be 2.35 multiplied by 105Da and has good immunoregulation activity.
The present invention is not limited to the above exemplary embodiments, and any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (5)
1. The Liuan Guapian polysaccharide with immunoregulation activity is characterized in that: the molecular weight of the Liuan Guapian polysaccharide is 2.35 × 105Da; the preparation method of the Liuan Guapian polysaccharide comprises the following steps:
(1) crushing Liuan Guapian tea leaves by a crusher, and sieving by a 80-mesh sieve to obtain powder;
(2) soaking the obtained powder in 50-80 deg.C anhydrous ethanol for 2-4h, filtering with gauze, and vacuum drying to obtain filter residue;
(3) leaching the obtained filter residue in hot water at 50-100 deg.C for 1-5 hr according to a material-liquid ratio of 1g:10-40mL, repeating for 2-3 times, and mixing extractive solutions;
(4) concentrating the extracting solution obtained in the step (3) to 1/3-1/10, adding ethanol into the obtained concentrated solution until the final volume concentration of the ethanol is 75-90%, standing for 8-12h at 4 ℃, centrifuging for 10-30min at 8000rpm of 5000-;
(5) dissolving the precipitate obtained in the step (4) with water, centrifuging to remove insoluble substances, and freeze-drying to obtain crude Liuan Guapian polysaccharide;
(6) preparing the crude polysaccharide of the Liuan Guapian tablet obtained in the step (5) into a crude polysaccharide solution with the concentration of 20-50mg/mL by using deionized water, centrifuging and filtering by using a 0.22 mu m filter membrane, putting the obtained trapped solution into a DEAE-cellulose 52 ion exchange column for purification, wherein the mobile phase is a 0.3mol/L sodium chloride solution, and the flow rate is 0.5-1.0 mL/min; collecting the product, purifying by using a dialysis bag, and freeze-drying to obtain the Liuan Guapian polysaccharide.
2. The Liuan Guapian polysaccharide having immunomodulatory activity, according to claim 1, wherein: in the step (2), the temperature of the vacuum drying is 60-70 ℃ and the time is 2-4 h.
3. The Liuan Guapian polysaccharide having immunomodulatory activity, according to claim 1, wherein: in the step (6), the molecular weight cut-off of the dialysis bag is 3.5kDa to 5.5 kDa.
4. The Liuan Guapian polysaccharide having immunomodulatory activity, according to claim 1, wherein: in the steps (5) and (6), the rotation speed of the centrifugation is 7000-10000 rpm.
5. The use of the polysaccharide of liuan guapian with immunomodulatory activity of claim 1, wherein: can be used for preparing immunomodulator.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110081907.5A CN112759663B (en) | 2021-01-21 | 2021-01-21 | Liuan Guapian polysaccharide with immunoregulatory activity and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110081907.5A CN112759663B (en) | 2021-01-21 | 2021-01-21 | Liuan Guapian polysaccharide with immunoregulatory activity and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112759663A CN112759663A (en) | 2021-05-07 |
CN112759663B true CN112759663B (en) | 2022-04-26 |
Family
ID=75702268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110081907.5A Active CN112759663B (en) | 2021-01-21 | 2021-01-21 | Liuan Guapian polysaccharide with immunoregulatory activity and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112759663B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101220100A (en) * | 2007-01-10 | 2008-07-16 | 兰州大学 | Separation and purification method for squash polyoses and use of obtained component |
CN102887962A (en) * | 2012-10-10 | 2013-01-23 | 安徽工程大学 | Method for preparing green tea polysaccharide through separation and purification and application of polysaccharide |
KR20150100599A (en) * | 2015-08-18 | 2015-09-02 | (주)아모레퍼시픽 | Method for preparing polysaccharide of green tea |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100010132A (en) * | 2008-07-22 | 2010-02-01 | (주)아모레퍼시픽 | Method for preparing polysaccharide of green tea |
CN105367679A (en) * | 2015-12-03 | 2016-03-02 | 镇江市丹徒区南山溪园茶叶专业合作社 | Green tea polysaccharide extraction method |
-
2021
- 2021-01-21 CN CN202110081907.5A patent/CN112759663B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101220100A (en) * | 2007-01-10 | 2008-07-16 | 兰州大学 | Separation and purification method for squash polyoses and use of obtained component |
CN102887962A (en) * | 2012-10-10 | 2013-01-23 | 安徽工程大学 | Method for preparing green tea polysaccharide through separation and purification and application of polysaccharide |
KR20150100599A (en) * | 2015-08-18 | 2015-09-02 | (주)아모레퍼시픽 | Method for preparing polysaccharide of green tea |
Non-Patent Citations (1)
Title |
---|
3种安徽名茶功能性成分浸出条件及茶渣资源化研究;陶梦婷 等;《食品安全质量检测学报》;20200321;第11卷(第2期);第368-374页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112759663A (en) | 2021-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102413705B1 (en) | Composition for improving liver function comprising Dendropanax morbifera extract | |
CN102579511B (en) | Method for integrally extracting steroidal compounds, polysaccharides and polyphenols from inonotus obliquus | |
US10835552B2 (en) | Method for preparing linseed polysaccharide having antiviral activity and immunological activity, and use of the linseed polysaccharide | |
AU2020103549A4 (en) | Novel se-enriched tea-derived ace inhibitory peptide and preparation process thereof | |
CN102071028A (en) | Method for preparing cupule antioxidant | |
CN102477104A (en) | Method for separating and purifying polysaccharide from Hovenia acerba | |
CN113425757A (en) | Dandelion extract and preparation method and application thereof | |
CN103505492B (en) | A kind of method using ultrafiltration to prepare high anti-oxidation value Radix Rhodiolae extract | |
CN113841894B (en) | Preparation method of lycium ruthenicum anthocyanin extract and freeze-dried powder and application of lycium ruthenicum anthocyanin extract and freeze-dried powder in antioxidant and anti-aging products | |
CN100463890C (en) | Highly effective extraction method for magnolol and honokiol crude extract | |
CN104292355B (en) | A kind of extracting method of platycodon root polysaccharide | |
CN112759663B (en) | Liuan Guapian polysaccharide with immunoregulatory activity and preparation method and application thereof | |
CN104744601B (en) | Method for extracting and purifying fleurotus ferulae polysaccharide | |
CN110066350A (en) | Blue or green money willow Polyose extraction and the method for blue or green money willow polysaccharide solid beverage preparation | |
CN102887962A (en) | Method for preparing green tea polysaccharide through separation and purification and application of polysaccharide | |
CN102988457A (en) | Total flavone extract of lonicera macranthoides leaves, and preparation method and application thereof | |
CN103864891A (en) | Chinese chive seed antioxidative tripeptide, and preparation and application thereof | |
CN102168120A (en) | Method for improving water solubility of grape seed proanthocyanidin | |
CN112521443B (en) | Preparation method and application of pseudo-ginseng flower protein | |
CN109954009A (en) | A kind of joint production process extracting SOD and general flavone from leaf of Moringa | |
CN1858045A (en) | Extracting method for Chinese toon old leaf flavone and saponin | |
CN101463052B (en) | Preparation of longan peel oligosaccharides | |
CN114159487A (en) | Method for extracting and purifying folium artemisiae argyi total flavonoids | |
CN108059686B (en) | Method for preparing polysaccharide based on pummelo peel | |
CN101200491B (en) | Rapid separation and purification method of cordyceps militaris fruit body water-soluble peptide polysaccharide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |